Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 294

1.

A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material.

Danila MI, Outman RC, Rahn EJ, Mudano AS, Thomas TF, Redden DT, Allison JJ, Anderson FA, Anderson JP, Cram PM, Curtis JR, Fraenkel L, Greenspan SL, LaCroix AZ, Majumdar SR, Miller MJ, Nieves JW, Safford MM, Silverman SL, Siris ES, Solomon DH, Warriner AH, Watts NB, Yood RA, Saag KG.

Contemp Clin Trials Commun. 2016 Dec 15;4:14-24.

PMID:
27453960
2.

Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.

Coburn BW, Cheetham TC, Rashid N, Chang JM, Levy GD, Kerimian A, Low KJ, Redden DT, Bridges SL Jr, Saag KG, Curtis JR, Mikuls TR.

Contemp Clin Trials. 2016 Jul 20;50:106-115. doi: 10.1016/j.cct.2016.07.019. [Epub ahead of print]

PMID:
27449546
3.

Evaluating the effectiveness of a patient storytelling DVD intervention to encourage physician-patient communication about nonsteroidal anti-inflammatory drug (NSAID) use.

Miller MJ, Weech-Maldonado R, Outman RC, Ray MN, Gary LC, Chen L, Cobaugh DJ, Allison JJ, Saag KG.

Patient Educ Couns. 2016 Jun 18. pii: S0738-3991(16)30277-4. doi: 10.1016/j.pec.2016.06.013. [Epub ahead of print]

PMID:
27380647
4.

Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial.

Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, Wright NC, Jones MP, Saag KG; PAADRN Investigators.

Osteoporos Int. 2016 Jun 30. [Epub ahead of print]

PMID:
27363400
5.

The National Osteoporosis Foundation's methods and processes for developing position statements.

Wallace TC, Bauer DC, Gagel RF, Greenspan SL, Lappe JM, LeBoff MS, Recker RR, Saag KG, Singer AJ.

Arch Osteoporos. 2016;11:22. doi: 10.1007/s11657-016-0276-1. Epub 2016 May 26.

PMID:
27229335
6.

Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.

Saag KG, Agnusdei D, Hans D, Kohlmeier LA, Krohn KD, Leib ES, MacLaughlin EJ, Alam J, Simonelli C, Taylor KA, Marcus R.

Arthritis Rheumatol. 2016 Sep;68(9):2122-8. doi: 10.1002/art.39726.

PMID:
27111239
7.

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.

Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR.

Arthritis Rheumatol. 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670.

PMID:
26990731
8.

Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.

Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L.

Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654.

PMID:
26894653
9.

Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.

Compston JE, Wyman A, FitzGerald G, Adachi JD, Chapurlat RD, Cooper C, Díez-Pérez A, Gehlbach SH, Greenspan SL, Hooven FH, LaCroix AZ, March L, Netelenbos JC, Nieves JW, Pfeilschifter J, Rossini M, Roux C, Saag KG, Siris ES, Silverman S, Watts NB, Anderson FA Jr.

J Bone Miner Res. 2016 Jul;31(7):1466-72. doi: 10.1002/jbmr.2810.

10.

Evaluating and mitigating fracture risk in established rheumatoid arthritis.

Mullen MB, Saag KG.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):614-27. doi: 10.1016/j.berh.2015.09.005. Epub 2015 Nov 12. Review.

PMID:
26697770
11.

Glucocorticoid-induced Osteoporosis.

Whittier X, Saag KG.

Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24. Review.

PMID:
26611558
12.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T.

Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6. Review.

PMID:
26545940
13.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6. Review.

PMID:
26545825
14.

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.

Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.

PMID:
26315675
15.

The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw.

Wright NC, Curtis JR, Arora T, Smith WK, Kilgore ML, Saag KG, Safford MM, Delzell ES.

PLoS One. 2015 Jul 10;10(7):e0131601. doi: 10.1371/journal.pone.0131601. eCollection 2015.

16.

An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users.

Warriner AH, Outman RC, Allison JJ, Curtis JR, Markward NJ, Redden DT, Safford MM, Stanek EJ, Steinkellner AR, Saag KG.

J Rheumatol. 2015 Aug;42(8):1478-83. doi: 10.3899/jrheum.141238. Epub 2015 Jul 1.

PMID:
26136484
17.

The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.

Yun H, Xie F, Delzell E, Chen L, Yang S, Saag KG, Joseph G, Harrison D, Curtis JR.

Br J Clin Pharmacol. 2015 Dec;80(6):1447-57. doi: 10.1111/bcp.12709. Epub 2015 Sep 30.

PMID:
26130274
18.

Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.

Santiago T, Jacobs JW, Saag KG, Buttgereit F, Pereira da Silva JA.

Acta Reumatol Port. 2015 Jan-Mar;40(1):10-22.

19.

Improving bone mineral density reporting to patients with an illustration of personal fracture risk.

Edmonds SW, Cram P, Lu X, Roblin DW, Wright NC, Saag KG, Solimeo SL; PAADRN Investigators.

BMC Med Inform Decis Mak. 2014 Nov 25;14:101. doi: 10.1186/s12911-014-0101-y.

20.

Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.

Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E.

Arthritis Rheumatol. 2015 Jun;67(6):1456-64. doi: 10.1002/art.39075.

Items per page

Supplemental Content

Write to the Help Desk